What complications and monitoring considerations should be observed in patients with rheumatoid arthritis?

Key Monitoring Priorities in Rheumatoid Arthritis

Patients with rheumatoid arthritis require systematic monitoring for cardiovascular disease, infections, extra-articular manifestations, treatment-related toxicities, and disease activity using validated measures to prevent joint damage and long-term complications.

Disease Activity Monitoring

Implement a treat-to-target approach with systematic monitoring using validated disease activity measures, initially targeting low disease activity with subsequent reassessment for remission. 1

• Monitor disease activity every 1-3 months using DAS28 or SDAI scores to guide treatment adjustments and minimize inflammation 1
• Assess three core domains at each visit: patient-reported physical function/global disease activity, physician assessment of disease activity, and imaging of hands/feet biannually 2
• Patient-reported measures of physical function, pain, and global disease activity are the most sensitive indicators of treatment response 2
• Clinical improvement does not always correlate with radiographic progression—both must be monitored independently 2

Cardiovascular Disease Surveillance

Cardiovascular disease is the leading cause of death in RA patients, with risk equivalent to diabetes mellitus. 3

• Screen aggressively for traditional cardiovascular risk factors (hypertension, hyperlipidemia, diabetes) as hypertension affects 35% of RA patients 4
• Monitor lipid profiles regularly, particularly when initiating or changing DMARDs 5
• Recognize that chronic inflammation itself drives cardiovascular risk independent of traditional factors 1, 3

Infection Risk Management

Glucocorticoids pose the highest infection risk in a dose-dependent manner—even low-dose therapy carries infection risk similar to biologics. 6

• Glucocorticoids at higher doses carry substantially greater infection risk than any other immunomodulatory therapy 6
• TNF inhibitors, other biologics, and JAK inhibitors all increase serious infection risk to similar degrees 6
• JAK inhibitors specifically increase herpes zoster risk beyond other agents 6
• Methotrexate has an excellent safety profile with relatively low infection risk compared to other agents 6
• Screen for latent tuberculosis and hepatitis B before initiating biologics or JAK inhibitors 6

Treatment-Related Laboratory Monitoring

Monitor liver transaminases, complete blood counts, and serum creatinine regularly for all patients on DMARDs. 5

• Check baseline complete metabolic panel, complete blood count, and hepatitis serologies before initiating DMARDs 5
• For methotrexate: monitor liver enzymes, creatinine, and blood counts every 2-4 weeks initially, then every 8-12 weeks once stable 5
• Monitor neutrophil and platelet counts for cytopenia risk across all DMARD classes 5
• Supplement with folic acid (at least 5mg weekly) to reduce methotrexate toxicity 1

Extra-Articular Manifestations

Screen for systemic complications affecting lungs, eyes, skin, heart, kidneys, and hematologic systems as these significantly impact prognosis and mortality. 7, 3

• Pulmonary: Monitor for interstitial lung disease with baseline chest imaging and pulmonary function tests, particularly before initiating methotrexate or biologics 7, 3
• Ocular: Screen for scleritis and episcleritis, which can be vision-threatening 3
• Hematologic: Watch for anemia of chronic disease, pure red cell aplasia, and myelodysplasia 3
• Renal: Monitor for amyloidosis and drug-related nephrotoxicity with serial creatinine and urinalysis 7, 3
• Vasculitis: Although increasingly rare with modern treatment, rheumatoid vasculitis remains a devastating complication requiring immediate recognition 3

Bone Health

Osteoporosis affects 32.6% of RA patients and requires proactive screening and management. 4

• Perform baseline DEXA scan at diagnosis and repeat every 1-2 years 4
• Risk is compounded by chronic inflammation, glucocorticoid use, and reduced mobility 4
• Initiate calcium, vitamin D supplementation, and consider bisphosphonates for high-risk patients 4

Psychosocial Comorbidities

Depression, anxiety, fibromyalgia, and fatigue are common comorbidities that persist despite disease control and require direct assessment. 3

• Screen for depression and anxiety using validated instruments at regular intervals 3
• Distinguish fibromyalgia pain from inflammatory pain to avoid inappropriate escalation of immunosuppression 3
• Address physical inactivity and fatigue as these impact quality of life independent of disease activity 3

Common Pitfalls to Avoid

• Do not rely solely on clinical remission—continue monitoring for radiographic progression as joint damage can occur even with apparent disease control 2
• Do not underestimate glucocorticoid toxicity—minimize dose and duration; even "low-dose" prednisone (<7.5mg daily) carries significant infection and cardiovascular risk 6
• Do not delay switching from oral to subcutaneous methotrexate in patients with inadequate response or intolerance before abandoning methotrexate entirely 1
• Do not ignore cervical spine involvement—assess clinically and radiographically as atlantoaxial instability can occur 2